These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 10367632

  • 1. No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma.
    Bockhorn M, Frilling A, Kalinin V, Schröder S, Broelsch CE.
    Langenbecks Arch Surg; 1999 Feb; 384(1):60-4. PubMed ID: 10367632
    [Abstract] [Full Text] [Related]

  • 2. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.
    Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y.
    J Hum Genet; 1998 Feb; 43(2):101-6. PubMed ID: 9621513
    [Abstract] [Full Text] [Related]

  • 3. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Feb; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 4. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ, Mulligan LM, Eng C.
    Horm Res; 1997 Feb; 47(4-6):168-78. PubMed ID: 9167949
    [Abstract] [Full Text] [Related]

  • 5. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma.
    Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Pfragner R, Behmel A, Lorenzo MJ.
    Genes Chromosomes Cancer; 1995 Mar; 12(3):209-12. PubMed ID: 7536460
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU.
    Cancer; 1995 Aug 01; 76(3):479-89. PubMed ID: 8625130
    [Abstract] [Full Text] [Related]

  • 8. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.
    Marsh DJ, Andrew SD, Eng C, Learoyd DL, Capes AG, Pojer R, Richardson AL, Houghton C, Mulligan LM, Ponder BA, Robinson BG.
    Cancer Res; 1996 Mar 15; 56(6):1241-3. PubMed ID: 8640806
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas.
    Zedenius J, Larsson C, Bergholm U, Bovée J, Svensson A, Hallengren B, Grimelius L, Bäckdahl M, Weber G, Wallin G.
    J Clin Endocrinol Metab; 1995 Oct 15; 80(10):3088-90. PubMed ID: 7559902
    [Abstract] [Full Text] [Related]

  • 12. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas.
    Scurini C, Quadro L, Fattoruso O, Verga U, Libroia A, Lupoli G, Cascone E, Marzano L, Paracchi S, Busnardo B, Girelli ME, Bellastella A, Colantuoni V.
    Mol Cell Endocrinol; 1998 Feb 15; 137(1):51-7. PubMed ID: 9607728
    [Abstract] [Full Text] [Related]

  • 13. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L.
    Eur J Endocrinol; 1997 Apr 15; 136(4):423-6. PubMed ID: 9150704
    [Abstract] [Full Text] [Related]

  • 14. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J, Wallin G, Hamberger B, Nordenskjöld M, Weber G, Larsson C.
    Hum Mol Genet; 1994 Aug 15; 3(8):1259-62. PubMed ID: 7987299
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S, Iwashita T, Asai N, Murakami H, Iwata Y, Sobue G, Takahashi M.
    Cancer Res; 1997 Jul 15; 57(14):2870-2. PubMed ID: 9230192
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A novel somatic mutation in the RET proto-oncogene in familial medullary thyroid carcinoma with a germline codon 768 mutation.
    Miyauchi A, Egawa S, Futami H, Kuma K, Obara T, Yamaguchi K.
    Jpn J Cancer Res; 1997 Jun 15; 88(6):527-31. PubMed ID: 9263528
    [Abstract] [Full Text] [Related]

  • 20. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
    Kameyama K, Okinaga H, Takami H.
    Biomed Pharmacother; 2004 Jun 15; 58(6-7):345-7. PubMed ID: 15271413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.